186267-75-4

Upstream product

• 75-44-5 phosgene 
• 65658-16-4 2-amino-6-methylbenzyl alcohol 
• 587-03-1 3-methylbenzyl alcohol 
• 201230-82-2 carbon monoxide 
• 54915-41-2 2-(hydroxymethyl)-3-methyl-1-nitrobenzene 

Downstream Products

• 186267-76-5 6-Bromo-5-methyl-1,4-dihydro-benzo[d][1,3]oxazine-2-one 
• 199452-41-0 piperidine-1-carboxylic acid 2-amino-5-bromo-6-methyl-3-nitrobenzyl ester 
• 199452-33-0 2-[(Benzyl-methyl-amino)-methyl]-4-bromo-3-methyl-6-nitro-phenylamine 

Relevant academic research and scientific papers

Versatile Cp*Co(III)(LX) Catalyst System for Selective Intramolecular C-H Amidation Reactions

Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed regioselectivity was rationalized by the conformational analysis and DFT calculations of the transition states. The superior performance of the newly developed cobalt catalyst system could be broadly applied to both C(sp2)-H and C(sp3)-H carbamation reactions under mild conditions.

A new synthetic method of 1,4-dihydro-2h-3,1-benzoxazin-2-ones: Selenium-catalyzed reductive carbonylation of aromatic nitro compounds with carbon monoxide

It was confirmed that selenium catalyzed the reaction of 2-nitrobenzyl alcohols with carbon monoxide to afford 1,4-dihydro-2H-3,1-benzoxazin-2-ones in good yields. Similarly, seven-membered cyclic carbamate was prepared by the reaction of 2-(2-nitrophenyl)ethanol with carbon monoxide.

Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists

A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer''s, Parkinson''s, and Huntington''s Diseases.